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Abstract 
Introduction 
Claudins [CLDN] are a new group of proteins that have of late attracted 
much attention as alterations in their expression is consistently associated with 
variations in outcomes in CA breast and many other malignancies. 
Aims & Objectives 
To study the association between the severity of disease, gauged by size of the 
primary tumour, clinical stage at presentation and the presence or absence of 
lymph node enlargement in breast cancer and, molecular subtype, as 
determined by the Estrogen and Progesterone receptor status and expression of 
Her2 neu, P53 Mutation, Ki 67 Index, expression of CLDNs 1, 3, 4 and 7 
Materials & Methods 
The study was conducted on female patients with CA breast who were 
managed in our department, regardless of age, stage of disease and 
management. Triple assessment was done and all data documented with 
regards to the patient, such as age, the tumour such as stage, histopathological 
type, hormone receptor status and HER2 neu. Immunohistochemistry was done 
to look for P 53 mutations and Ki 67 Index. RT PCR was done to assess the 
expression of Claudin genes 1, 3, 4 and 7.  
Results 
 There was a statistically significant association between the 
expression of CLDNs 1, 3, 4 and 7 and the presence of clinically or 
radiologically suspicious lymph nodes, ER status (PR status was associated 
with CLDN 4 expression alone), triple negative tumours, P 53 mutation, and Ki 
67 index.  
There was no association, however, with the age of the patient, clinical 
stage at presentation, tumour size, HER 2 neu expression and that of CLDN 1, 
3 and 7 with PR status. 
Conclusion 
The results indicate that several associations and their implications have 
to be kept in mind while managing breast cancer and we can no longer stop 
with the standard protocols. Newer methods of prognostication are required. 
Promising drugs that target claudins are in clinical trials and they may improve 
the outcome drastically in these patients. Further studies will help clarify this 
information further 
Key Words: breast cancer, claudins, claudin low breast cancer, triple negative 
breast cancer, P 53, Ki 67, estrogen receptor, progesterone receptor, HER2neu, 
molecular subtyping of breast cancer.  
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INTRODUCTION 
 While an enormous amount of information still remains 
intricately hidden with the human genome, research today is slowly but 
steadily decoding it. Every piece of data thus garnered alters to some 
extent our current understanding of malignancies and opens up new 
avenues for their management. 
Carcinoma [CA] of the breast is one of the most common 
malignancies encountered in the General Surgery Out Patient 
Department  & operated on at ESIC Medical College & PGIMSR. 
Patients, mainly from lower socioeconomic strata, often present with 
either palpable lump or in a more advanced stage. 
They are treated as per standard protocols with: 
 Modified Radical Mastectomy followed by Adjuvant 
Chemotherapy, Radiation or both in early breast carcinomas,  
 Neoadjuvant Chemotherapy followed by Surgery, Adjuvant 
Chemotherapy and Radiation in locally advanced breast cancer 
and  
 Palliative Chemotherapy for advanced metastatic disease.  
The follow up in our hospital is excellent as this is a tertiary care 
center for the ESI beneficiaries of this region. For a condition such as 
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cancer of the breast, all the patients are treated here and it is possible to 
follow the patient from initial presentation, through diagnosis, 
treatment and during adjuvant therapy as well, except in rare 
extenuating circumstances.  
While the standard of care is being met, the number of patients 
who came back with poor control of the primary and recurrences was 
glaringly high and the need to look beyond the regular protocols to 
establish a new standard of care arose. 
The treatment of malignancies now a day is based on the 
molecular biology of the cancer in general and the individual in 
particular. It is clear that our understanding of the molecular genetics 
of carcinoma of the breast is still at a very rudimentary level, as 
evidenced by the mortality and morbidity associated with the disease. 
More molecular targets need to be identified for appropriate drugs to 
be developed.  
Claudins [CLDN] are a new group of proteins that have of late 
attracted much attention as alterations in their expression is 
consistently associated with variations in outcomes in CA breast and 
many other malignancies. While the overall outcomes in breast cancer 
have improved, those of patients with alterations in claudin expression 
continue to be poor. These tumours behave differently and standard 
chemotherapy is not as effective in their management. Claudins are a 
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veritable treasure trove of potential targets for treatment. These 
therapeutic agents are also expected to be highly specific in their site of 
action, thus avoiding all the unpalatable side effects of cancer 
chemotherapy. Promising new drugs are already in clinical trials.  
In this study, the molecular subtypes according to hormone 
receptor status and Ki 67 index were ascertained, as were the presence 
P53 mutations and expression patterns of CLDNs 1, 3, 4 and 7. 
Associations between disease severity and these parameters and 
associations among these parameters were analyzed statistically.  
Assessing the molecular profile of every breast cancer will soon 
be the norm. Only when we are able to categorically determine every 
genetic nuance of a malignancy will we be able to treat it with finality. 
Until that point there will always be lacunae.   
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AIMS AND OBJECTIVES 
 To study the association between the severity of disease, gauged 
by size of the primary tumour, clinical stage at presentation and 
the presence or absence of lymph node enlargement in breast 
cancer and: 
o Molecular subtype, as determined by the Estrogen and 
Progesterone receptor status and expression of Her2 neu 
o P53 Mutation 
o Ki 67 Index 
o Expression of CLDNs 1, 3, 4 and 7 
 To establish a baseline demographic, hormonal and genetic profile 
of female patients with Carcinoma breast managed in our hospital 
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MATERIALS & METHODS 
The study was conducted on patients with Carcinoma [CA] of 
the breast attending the surgical Out Patient Department (OPD) of 
ESIC Medical College & PGIMSR, K K Nagar, Chennai 
Inclusion Criteria 
 All female patients with CA breast, regardless of age, stage of disease and management. 
Exclusion Criteria 
 Male patients with Carcinoma breast 
Sample Size 
In a study published in 2011, Campbell et al quoted the 
prevalence of claudin low subtype of breast cancer as 7 – 14%. Taking 
an average prevalence of 11%, the minimum number of patients 
needed to estimate the association with 95% confidence and a 
precision of 9% was found to be 46. A sample size of fifty patients was 
taken in this study 
When a patient with a suspicious breast lump was encountered, the 
protocol of ‘Triple Assessment was followed: 
 
 
*RT-PCR  **IHC 
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This data was documented. The size of the primary tumour, 
clinical stage and mammographic findings were taken as markers of 
the severity of the disease at presentation. Trucut biopsy was used as 
the standard method of tissue diagnosis. Immunohistochemistry tests 
were run on the same samples for hormonal receptor status, P53 
mutation and Ki 67 index.  
Biopsy samples were placed in the preservative issued by the 
laboratory and frozen. RT PCR was then done for the expression of 
CLDN 1, 3, 4 and 7.  
Patients were categorized as having Early, Locally Advanced or 
Metastatic Breast Cancer. They patients were subjected to Surgery, 
Neoadjuvant chemotherapy [NACT] followed by Surgery or Palliative 
Chemotherapy.  
 
         
18  
    
REVIEW OF LITERATURE 
Embryology of the Breast1 
 The breast is a modified 
sweat gland derived from the 
epidermis. A localized proliferation of 
the stratum spinosum of the epidermis 
of that region gives rise to the nipple. 
During the second month of gestation, 
two bands of slightly thickened ectoderm appear on the ventral body 
wall extending from above the axilla to below the groin. These bands 
are the milk lines and represent potential mammary gland tissue.  
 
   
                                                    Fig 2: Development of Secretory Unit  
In humans, only the pectoral portion of these bands will persist 
and ultimately develop into adult mammary glands. Occasionally, 
vestigial, or even functional, breast tissue may arise from other portions 
Fig 1: Milk Line 
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of the milk line 
The glandular tissue of the breast arises from the local 
thickening of the epidermis from which, 16 to 24 buds of ectodermal 
cells grow into the underlying mesoderm at the twelfth week of 
intrauterine life. These buds are initially solid, but become canalized 
close to term resulting in the lactiferous ducts. The terminal parts of the 
buds will give rise to the secretory acini at the time of lactation. The 
epidermal portion of the future nipple first appears as a shallow pit, 
which everts as the fetus approaches term. The areola is said to be 
visible from the fifth month onward.  
Gross Anatomy 1 
The breast lies in the superficial 
fascia of the anterior thorax. The vertical 
extent is from the second to sixth ribs and 
the horizontal extent is from the sternum to 
the mid-axillary line. It consists of ducts 
and secretory lobules. The ducts converge to form 15 – 20 secretory 
lobules that open on to the nipple. The pigmented areola surrounds the 
nipple. 
Fig 3: Anatomy of the Breast 
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The connective tissue stroma that surrounds the ducts and 
lobules of the breast condenses to form 
the Suspensory ligaments of breast in 
some regions, which are attached to the 
dermis of the overlying skin and support 
the breast. Fat content is more abundant 
in non-lactating women while glandular 
element is more in those who are 
lactating.  
The breast is related posteriorly to the deep fascia covering the 
Pectoralis major muscle, from which it is separated by loose 
connective tissue known as the retromammary space. This enables 
movement of the breast over the underlying structures. 
The upper lateral part of the breast can extend around the lateral 
margin of the pectoralis major muscle and into the axilla as the axillary 
tail. It may extend up to the axillary apex.     
Blood Supply    
 Arterial supply arises medially from the branches of the internal 
mammary and the second to fourth intercostal arteries through 
perforators and laterally from those of the axillary artery. Venous 
drainage follows the arteries and finally reach either the axillary, 
internal thoracic or the intercostal veins. 
Fig 4: Relations of the Breast  
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Nerve Supply 
The breast gets its nerve supply from the anterior and lateral 
cutaneous branches of the second to sixth intercostal nerves. The 
sensory supply to the nipple is by the fourth intercostal nerve. 
Lymphatic Drainage 
Nearly three fourths of the lymph from the breast drains in to the 
axillary nodes with most of the remainder going to the internal thoracic 
nodes. A small quantity of lymph may drain along the lateral branches 
of the posterior intercostal nodes to reach the intercostal nodes. 
Physiology of the Breast 2 
 Several hormonal stimuli are responsible for breast development 
and function. They are Estrogen, Progesterone, Prolactin, Oxytocin, 
Thyroid hormone, Cortisol and the Growth hormone.  
Estrogen is responsible for ductal development, and 
progesterone for differentiation of epithelium and for lobular 
development. Lactogenesis is stimulated by Prolactin during late 
pregnancy and the postpartum period. It causes upregulation of 
hormone receptors and aids in epithelial development. In Figure 5, the 
secretion of hormones that regulate the function and development of 
breast tissues is represented. Positive and negative feedback 
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mechanisms exercise stringent control of the hormones secreted from 
the hypothalamus and the pituitary.  
 
 
The female breast changes dramatically as it goes through the 
various developmental stages in adolescence, pregnancy, lactation and 
senescence. These changes are governed by the complex interactions 
among the various hormones. Imbalances in these hormones result in 
several conditions, both benign and malignant, involving either the 
glandular portion or the stroma. 
Fig 5: Regulation of Breast Development & Function 
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Carcinoma of the Breast 
Carcinoma of the breast is epithelial malignancy arising from 
breast tissue and can originate from either the lobules or the ductules.  
Risk Factors for Carcinoma Breast3-9 
Hormonal Risk Factors 
Breast cancer increases with the increase in exposure to 
estrogen. The converse is thought to be protective. The former occurs 
when the number of menstrual cycles is increased. This is seen with 
early menarche, late menopause and nulliparity. On the other hand, 
exercise and a longer lactation period are protective. The epithelium of 
the breast only attains terminal differentiation with a full-term 
Fig 6: Physiological Stages of Breast Development 
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pregnancy and the younger the age at which this occurs, the lower the 
risk. Following menopause, estrogen is primarily derived from estrone, 
derived from androstenedione in the adipose tissue. Hence, in an obese 
woman the estrogen exposure is more, which translates in to a higher 
risk. 
Nonhormonal Risk Factors 
Theses include radiation exposure, especially if such exposure 
occurs during the time of active breast development. In the bygone era 
of mantle radiation therapy for Hodgkin's lymphoma, those women 
who received it had a substantially higher breast cancer risk than the 
normal population. Survivors of the nuclear fallout of World War II in 
Japan developed several radiation induced somatic mutations. Alcohol 
consumption increases the risk, as it is directly proportional to the 
amount of alcohol consumed. Alcohol increases estradiol levels.  In 
addition, a high fat diet increases the breast cancer risk, also attributed 
to raised serum estrogen levels.  
Risk Assessment Models2 
The breast cancer risk decreases with advancing age. A fifty-
year-old woman has a lifetime risk of 11% for the disease, while a 
seventy-year-old, 7%. There is marked interaction between the various 
risk factors. When several factors are present, risk evaluation is 
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difficult. Two risk assessment models are in popular use for such 
prediction. The most frequently used model is the Gail Model, which 
resulted from the “Breast Cancer Detection Demonstration Project”, a 
mammographic screening programme.  
 
The cumulative risk of breast cancer in each decade of life can 
be predicted using the Gail Model, where the relative risks from 
various categories are multiplied to arrive at an overall risk. Comparing 
the overall risk to that of an adjusted population then arrives at a 
woman’s individual risk.  
Data gathered in “Cancer and Steroid Hormone Study”, a case-
control study of breast cancer, led to the development of the Claus 
Table 1. Various Risk Assessment Models for CA Breast 
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Model by Claus and colleagues. It incorporates more data about family 
history of the disease and the breast cancer risk is estimated for the 
decade of life based on presence of first- and second-degree relatives 
with breast cancer and their age at diagnosis. Risk factors that are less 
consistently associated with breast cancer such as diet, use of oral 
contraceptives and lactation, and those that are rare in the general 
population like radiation exposure are included in neither model. 
Several other models also exist. None of these models accounts for the 
risk associated with mutations in the breast cancer susceptibility genes 
BRCA1 and BRCA2. 
Risk Management10-18 
The risk of developing breast cancer will dictate several 
important medical decisions, such as:  
 The usage of postmenopausal hormone replacement therapy 
 The age at which mammography screening is to be started 
 The use of Tamoxifen to prevent the disease 
 The decision to perform mutilating surgery such as prophylactic 
mastectomy 
Postmenopausal hormone replacement therapy was widely 
prescribed in the 1980s and 1990s because of its effectiveness in 
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controlling the symptoms of estrogen deficiency. However, large-scale 
phase III clinical trials, the results of which were released in 2002, 
showed conclusively that breast cancer risk is threefold to fourfold 
higher after >4 years of use and there is no significant reduction in 
cardiac or cerebrovascular events. 
In women at or over the age of fifty, screening mammography, 
routinely used, reduces mortality from breast cancer by 33%. There are 
no significant risks involved and it is cost effective. Although its 
routine use in women less than fifty years of age is more controversial, 
the benefits of screening mammography between the ages of 40 and 49 
years still appear to trump the risks. Reserving mammography for 
women known to be at a higher risk of the disease may also improve 
the risk – benefit ratio. For example, a mammographic abnormality in a 
woman with a family history of breast cancer is three times more likely 
to be malignant than in one without such a history. In addition, 
mounting data regarding mammographic breast density demonstrate an 
independent correlation with breast cancer risk. It is currently 
recommended that women undergo baseline mammography at age 35 
and then have annual mammographic screening beginning at age 40. 
Tamoxifen, a selective estrogen receptor modulator, has been 
conclusively shown to reduce the incidence of CA breast in healthy 
women.  
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Prophylactic mastectomy, where indicated, would reduce the 
risk of breast cancer by over 90%. However, several long-term quality 
of life issues remain to be addressed. The benefit varies with the risk of 
developing the disease. When the estimated lifetime risk is 40%, the 
procedure added almost 3 years of life, while with a risk of 85%, 
prophylactic mastectomy added more than 5 years of life. 
BRCA Mutations19-25 
 Inherited germline mutations such as those of BRCA1 and 
BRCA2account for five to ten per cent of breast cancers. They are 
tumor-suppressor genes, and for each gene, loss of both alleles must 
occur before cancer occurs. They are inherited in an autosomal 
dominant pattern with variable penetrance (Table 2). Hence, 50% of 
offspring of carriers inherit the trait. It is likely that these genes are 
coregulated. 
 Germline mutations in BRCA1 are a predisposing genetic factor 
in as many as 45% of hereditary breast cancers and in at least 80% of 
hereditary ovarian cancers. More than 500 variations in sequence have 
been documented. The BRCA2 gene is unlike any other gene identified 
so far, and the protein is also unique. More than 250 mutations have 
been found till date. In male carriers, there is an estimated breast 
cancer risk of 6%, which represents a hundred times higher risk than 
the general male population.  
29  
 BRCA1 BRCA2 
Location Chromosome 17q Chromosome 13q 
Size 100 kb 70 kb 
Exons 22 26 
mRNA - 7.8 kb - Encodes a 1863 amino acid protein 
- 11.2 kb - Encodes a 3418 amino acid protein 
Inheritance Autosomal Dominant Autosomal Dominant 
Functions - Transcription - Cell cycle control 
- DNA damage repair pathways 
- Not well defined 
Distinguishing Features - Earlier age of onset than sporadic cases - Higher incidence of bilateral breast cancer 
- Earlier age of onset than sporadic cases - Higher incidence of bilateral breast cancer 
Breast Cancer (Females) 90% 85% 
Lifetime Risk of Ovarian Cancer (Females) - 40% - Invasive ductal carcinoma - Poorly differentiated - Hormone receptor negative 
- 20% - Invasive ductal carcinoma - Well differentiated - Hormone receptor positive 
Associated Malignancies Colon and prostate cancers.  
Colon, prostate, pancreatic, gallbladder, bile duct, stomach cancers, and melanoma. 
 Table 2.  Characteristics of BRCA1 & BRCA2 Mutations 
Hereditary breast cancer is likely if: 
 A family includes two or more women who developed ovarian 
cancer or breast cancer before age 50 years.  
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 Any woman diagnosed with breast cancer before age 50 years or 
with ovarian cancer at any age is asked about first-, second-, and 
third-degree relatives on either side of the family with either of 
these diagnoses.  
 Breast and ovarian cancer in the same individual  
 Male breast cancer at any age 
When such a scenario arises, the most prudent strategy is first to 
completely analyze the sequence of both genes in the patient. When a 
mutation is found, relatives can be tested for that particular mutation 
alone. If the mutation is not identified in the relatives, complete 
sequencing needs to be done.  
Risk management strategies for these patients are: 
     Prophylactic mastectomy and reconstruction 
   Prophylactic oophorectomy and hormone replacement therapy 
   Diligent surveillance for breast and ovarian cancer 
   Chemoprevention 
 Present screening recommendations in those patients who 
choose not to undergo prophylactic procedures are: 
 Breast examination by a doctor every 6 months  
 Yearly Mammography starting at the age of 25 years 
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       The risk of breast cancer in carriers of these mutations is higher 
after 30 years of age. MRI is the more sensitive screening investigation 
in younger women with dense breasts26.  
        Cancers arising in the setting ofBRCA1 mutation are usually high 
grade and often ER, PR and HER2 neu negative. 66% of BRCA1-
associated DCIS lesions are estrogen receptor negative, which indicates 
that the hormone-independent phenotype is an early phenomenon in the 
evolution of the disease.   
The introduction of the poly (ADP-ribose) polymerase (PARP) 
inhibitors has opened up new therapeutic possibilities for these 
patients. They have a lethal effect on affected cells by targeting an 
alternate DNA repair pathway in BRCA-deficient cells. A phase II trial 
of one PARP inhibitor was recently published, showing promising 
survival data in patients with triple-negative metastatic disease. 
Other Hereditary Syndromes  
  Cowden disease (PTEN mutations, in which cancers of the 
thyroid, GI tract, and benign skin and subcutaneous nodules are 
also seen) 
  Li-Fraumeni syndrome (p53 mutations, also associated with 
sarcomas, lymphomas, and adrenocortical tumors)  
  Syndromes of breast and melanoma 
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Presentation of CA Breast 
In our country most patients present to the hospital after they 
detect a lump. With increase in awareness, patients are presenting 
earlier. However, there remains a small fraction who present with 
advanced disease.  
When a patient presents to the hospital with a suspicious lump, 
the triple assessment is carried out which consists of clinical 
examination, radiological assessment and confirmation of the diagnosis 
with a tissue sample. Once the diagnosis of carcinoma breast is 
established, a metastatic work up is performed with the investigations 
warranted by the clinical scenario. We then have all the information we 
need to arrive at the Stage of the malignancy (Fig 7).  
Then the patients can be classified into Early Breast Cancer 
(EBC), Locally Advanced Breast Cancer (LABC) or Metastatic disease 
and are treated accordingly.  
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Table 3: TNM Staging of CA Breast with Approximate 5-Year Survival Rate 
Evolution of Treatment Principles of CA Breast2 
‘Cancer’ as described and compared to the crab is probably best 
exemplified by the carcinoma of the breast.  
The very first documentation of the disease, the Smith Surgical 
Papyrus, dates back to 3000 – 2000 BC, and describes the malignancy 
34  
in, interestingly enough, a male patient with the conclusion that the 
condition was simply not curable. Very few other such descriptive 
texts have been discovered up until the first century. Celsus in the ‘De 
Medicina’ categorically states that except the ‘cacoethes’ or early 
breast cancer, this condition remains largely incurable. He observed, in 
fact, that attempting surgery in any of the advanced conditions only 
made the disease more aggressive. The Galenic system, that dictated 
much of medicine up until the Renaissance, shared the same principle. 
Time Frame Surgeon Innovation 
18th Century Morgagni Resection 
Le Dran Theory of lymphatic spread 
19th Century Moore Mastectomy 
Banks Mastectomy with removal of nonpalpable lymph nodes 
Halstead & Meyer Radical Mastectomy 
Patey Modified Radical Mastectomy 
 Table 4.  Milestones in Breast Cancer Management 
 
Later on, Morgagni and others of his time started attempting 
surgical resections. Le Dran postulated the theory of lymphatic spread 
and began excising all enlarged lymph nodes during surgery.  
The removal of the affected breast in toto, along with all 
palpable lymph nodes, was first advocated by Moore, of the Middlesex 
County hospital in London in the nineteenth century. Banks, supported 
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his methods, drew attention to the possibility of micrometastasis and 
emphasized that non-palpable lymph nodes should also be removed.  In 
1894, Halstead & Meyer presented their experience with radical 
mastectomy including complete excision of nodes Level I to III, long 
thoracic nerve and thoracodorsal neurovascular bundle with axillary 
contents. Then came Patey’s modified radical mastectomy where the 
pectoralis major was preserved, while the pectoralis minor was excised 
to reach and remove the Level III nodes. Further modifications of this 
procedure preserved the pectoralis minor as well, with division or 
retraction being employed to access Level II lymph nodes 
The Current Perspective 
Carcinoma of the breast is a multifactorial and systemic disease. 
It is the most common malignancy in women worldwide, but for skin 
cancer. More than a million cases diagnosed a year.  
Earlier diagnosis & better treatment modalities have improved 
prognosis and the focus has shifted to molecular targets for therapeutic 
manipulation27. Tailoring therapy to the individual patient has become 
the norm. 
In the past 20 years there has been a substantial increase in our 
understanding of carcinogenesis and the role of genetic alterations in 
the diagnosis, treatment, and prevention of breast cancer. Gene 
expression studies have been adopted for both molecular and 
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phenotypic characterization and for therapeutic decision-making in 
breast cancer treatment. 
Molecular Subtypes of Carcinoma Breast28 
 The molecular subtyping of carcinoma breast is based on the 
hormone receptor status and tumour grade. 
Molecular Subtype Hormonal Profile Others 
ER PR HER 2  
Luminal A + +/- - Low Ki 67 
Luminal B + +/- +/- High Ki 67 
HER 2 Enriched     
Basal Like - - -  
 Table 5.  Molecular Subtype of CA Breast 
These breast tumour subtypes suggest arrest of development at 
different stages of epithelial cell differentiation. 
 
 
 
 
 
 
Fig 7.  Mammary Cell Development and Stages Where Malignancy Develops 
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Basal-Like Breast Cancer 
This group of tumours constitutes an average of 10%–25% of all 
tumors and make up about 50%–75% of the triple-negative subtype29. 
The triple-negative cancers may, less often, be of the other intrinsic 
subtypes. The distinguishing features are: 
 Arise from progenitors early on in mammary cell development 
 Express cytokeratins 5, 6, or 17, that are seen in the basal 
epithelial layer of the skin and airways 
 Deficient in critical cell cycle regulators, p53 & RB1, thus 
making them highly proliferative 
 Associated with BRCA1 Mutation 
 High aneuploidy, several chromosomal changes, translocations, 
and losses. 
The prognosis of basal like tumours is poor, making it 
imperative to identify suitable therapeutic targets in these patients30. 
The benefit of standard chemotherapy in these patients is questionable. 
Trials are underway to assess the responsiveness of these tumours to 
regimens with and without carboplatin. Potential Therapeutic Targets 
for these tumours include29: 
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 SRC (Non Receptor Tyrosine Kinase) Inhibition 
 PARP Inhibition 
 Androgen Receptor Inhibition 
 Targeting Epigenetics 
 EGFR Inhibition 
 Phosphatidylinositol 3-kinase (PI3K)Pathway Inhibition 
 Antiangiogenetic therapy (Bevacizumab) 
Tight Junctions 31-33 
Tight junctions [TJ] regulate cell adhesion. They consist of 
transmembrane and peripheral membrane proteins.  
 
 
 
 
 
Fig 8: Components of Tight Junctions 
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They are involved in: 
 Interactions among proteins 
 Maintenance cell polarity  
 Controlling paracellular ion flux.  
Claudins (CLDN) are integral membrane proteins of TJs and 
include 24 genes in mammals34. In human beings, of the 23 of the 24 
claudin genes have been identified, with the exception of CLDN13. 
These are small genes that have few introns. Some are located close to 
each other and contain strikingly similar sequences, such as CLDN6 
and CLDN9 on chromosome 16, CLDN22 and CLDN24 on 
chromosome 4, CLDN8 and CLDN17 on chromosome 21, and CLDN3 
and CLDN4 on chromosome 7. This is indicative of generation by gene 
duplication, and that adjacent genes may be coordinately regulated34. 
Others are diverse.  
They are most commonly 20–34 kDa in size. They have four 
transmembrane helices with amino- and carboxyl-terminal tails 
extending into the cytoplasm34, 35.  
Claudins have two extracellular loops, the first extracellular loop 
containing charged amino acids that play a vital part in paracellular ion 
selectivity36. 
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Table 6: Human Claudin Genes (NA: Not Available) 
 The carboxy-terminal tails vary both in size and sequence among 
different claudin proteins that allows interaction with cytoplasmic TJ-
associated proteins. This is also the site of post-translational 
modifications that determine localization and functions of claudins.  
Claudins are expressed in different patterns in different tissues, 
and multiple claudins are expressed in most tissues36.  
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 CLDN 2 and CLDN 15: Cation channels  
 CLDN 4, 7 and 10 Anion channels/pores.  
The expression of claudins is regulated by: 
 Transcription factors 
 Epigenetic mechanisms 
 Post-transcriptional level.  
 Growth factors 
 Nonsteroidal anti-inflammatory drugs (NSAIDS) such as aspirin 
reduce claudin-7 expression in gastric epithelial cancer cells.  
Several human diseases have been linked to mutations in claudin 
genes: 
 CLDN1: Sclerosing cholangitis, ichthyosis   
 CLDN16 and CLDN19: Hypomagnesemia, hypercalcinuria 
 CLDN3 and CLDN4: Receptors for the Clostridium perfringens 
enterotoxin (CPE) 
 CLDN1, 6 and 9 : Co-receptors for the hepatitis C virus  
 CLDN1, 3, 4 and 7 are commonly dysregulated in cancer 
          These proteins have prognostic significance and are viable 
therapeutic targets. 
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Epithelial to Mesenchymal Transition 
Significant heterogeneity is seen among breast cancers. There is 
a small population of self-renewing “cancer stem cells” or “tumor-
initiating” cells (CSC/TICs), that are involved in tumour formation, 
chemoresistance and recurrence37. They can arise from fully 
differentiated cells by a phenomenon known as “epithelial to 
mesenchymal transition” (EMT)37,38.  
 In the claudin low subtype of CA breast, cell–cell junction 
proteins, including E-cadherin, are lacking. A growing number of 
studies suggest that claudins are involved in the regulation of 
CSC/TICs and chemoresistance39. Features of EMT are seen in them. 
In addition, they are consistently associated with an intense immune 
cell infiltrate40. 
Claudins in Tumor Progression  
Claudin expression varies in a tissue-specific manner and they 
have different effects on different malignancies (Table 3).  
 
 
 
 
Fig 9: Role of Claudins in Cancer Cell Invasion 
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Table 3: Role of Claudins in Human Cancers 
Claudins Cancer Function In vitro orin vivo Role
Claudin-1 Breast Increase of cell migration In vitro Cancerpromoting
Breast Anti-apoptotic effect In vitro Cancerpromoting
Colon Increase of invasion and metastaticbehavior In vitro & invivo Cancerpromoting
Liver Increase of invasion In vitro Cancerpromoting
Liver Induction of EMT In vitro Cancerpromoting
Melanoma Increase of cell motility and invasion In vitro Cancerpromoting
Oral Increase of invasion In vitro Cancerpromoting
Gastric Inhibition of tumorigenicity In vivo Tumorsuppressive
Lung Inhibition of cell migration and invasion,in vivo metastasis In vitro & invivo Tumorsuppressive
Claudin-3 Ovarian Increase of invasion In vitro Cancerpromoting
Ovarian Promoting in vivo tumor growth andmetastasis In vivo Cancerpromoting
Ovarian Inhibition of in vivo tumor growth andmetastasis In vitro & invivo Tumorsuppressive
Ovarian Suppression of EMT In vitro & invivo Tumorsuppressive
Claudin-4 Ovarian Increase of invasion In vitro Cancerpromoting
Ovarian Stimulation of angiogenesis In vitro & invivo Cancerpromoting
Gastric Inhibition of migration and invasion In vitro Tumorsuppressive
Ovarian Suppression of EMT In vitro & invivo Tumorsuppressive
Pancreatic Suppression of cell invasion andmetastasis In vitro & invivo Tumorsuppressive
Claudin-6 Gastric Increase of proliferation, migration andinvasion In vitro Cancerpromoting
Breast Inhibition of anchorageindependentgrowth In vitro Tumorsuppressive
Breast Inhibition of anchorageindependentgrowth, migration and invasion In vitro Tumorsuppressive
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Epithelial integrity is lost during malignant transformation due 
to loss of epithelial integrity that results from deranged TJ function that 
causes cells to lose polarity41. So it was assumed that loss of claudin 
expression contributed to tumor progression. However, growing 
evidence suggests that increased expression of claudins maybe 
involved in invasion and metastasis (Table 3). Mislocalization of 
claudins may have in addition, a role in tumorigenesis and increases 
paracellular permeability.  
A number of signaling pathways participate in claudins mediated 
malignant change.  For example, increased expression of claudin 2 is 
associated with increased incidence of hepatic metastasis. 
 
Fig 10: Claudin 2 & Hepatic metastasis in CA Breast 
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Claudin 1 
Claudin 1 is deranged in several human cancers. It is probably 
the most commonly affected claudin. It has different roles in different 
cancers, causing in tumour suppression in some and progression in 
others.  
 
 
 
 
 
Fig 11: Claudin 1: Molecular Structure 
 Invasion and metastasis are probably the most commonly 
mediated phenomena in cells with altered claudin expression. Loss of 
CLDN1 in basal-like breast cancer cells decreases cell migration42.  
However, it has an anti-apoptotic effect in tamoxifen-treated 
human breast cancer cells and a tumor suppressive role in gastric 
cancer and lung cancer.  
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 Fig 12: A hypothetical model of claudin 1 expression in  different breast cancer subtypes.  
 
Claudin 3 and Claudin 4  
These genes are frequently dysregulated in ovarian cancer. 
Claudin 4 increases the production of angiogenetic factors. Metastasis 
of breast or ovarian cancers may be enabled by CLDN4 by interactions 
with extracellular matrix proteins43.  
 
 
 
 
 
Fig 13: Claudin3: Molecular Structure 
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The loss of expression of CLDN 3 and 4 during tumorigenesis, 
maybe responsible for the low expression of E-cadherin, CLDN1 and 7 
in the claudin-low breast cancer subtype44,45.  
A tumor suppressive role has also been associated with these 
genes in many cancers. Metastatic potential has been found to be 
reduced in pancreatic cancer. Several reports indicate that decreased 
expression of CLDN4 is linked to bad prognosis in breast, esophageal, 
colon and pancreatic cancers. It is thus postulated that claudin-4 
probably plays a tumor suppressive role in these malignancies. 
Claudin-7  
Loss of Claudin-7 expression has been shown to be associated 
with rapid cell growth and invasion, probably as it causes loss of E-
cadherin. Re-expression of normal levels of CLDN7 resulted in 
restoration of E cadherin function46. 
 
 
 
 
Fig 14: Claudin 7: Molecular Structure Molecular Structure 
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Evidence suggests that loss of CLDN 7 expression correlates 
with the grade of ductal carcinoma in situ and infiltrating ductal 
carcinoma. Alterations are also seen in lobular carcinoma in situ.  It 
may thus promote tumor progression. CLDN7 overexpression in 
colorectal cancer cells disrupts cell polarization and enhances β-catenin 
activity and cell proliferation. This promotes tumor formation in vivo 
in xenograft mice injected with CLDN7 overexpressing colorectal 
cancer cells. Similar effects are seen in ovarian cancer cells.  
Claudin Low Molecular Subtype of Breast Cancer 
This newer molecular subtype of CA breast has lowered 
expression of CLDN1, CLDN3, CLDN4, CLDN7 and CDH1due to 
deranged tight junctions. These tumors are often triple-negative breast 
cancers, which lack the expression of estrogen, progesterone and 
epidermal growth factor receptor 2 (HER2). Stromal contamination or 
tumour-associated fibroblasts may be responsible for the mesenchymal 
features of these tumours. Several aspects of these tumours are not well 
understood and further evaluation is needed to understand them 
better45. They are characterized by an intense inflammatory infiltrate.  
Several recent studies have shown that in the claudin low 
tumours, there in an increased generation of breast CSC/TICs. They 
are capable of better self-renewal in vitro, enhanced in vivo 
tumorigenicity and increased resistance to conventional chemotherapy. 
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There is sufficient evidence to suggest that they are generated by 
EMT44. 
Whether the loss of claudin expression is a cause or effect of this 
process remains to be conclusively determined in the claudin-low 
subtype of breast cancer. But there is little doubt that the role of 
claudins in CSC/TICs is becoming more apparent, and they may be 
promising new targets in the treatment of cancer.  
Claudins in Chemoresistance  
Failure of therapy usually occurs due to non-responsiveness of a 
particular tumour to chemotherapy47. Similar to antibiotic resistance, 
deciphering the causes for chemoresistance is imperative. 
In a recent study it was seen that claudin 7 expression in lung 
cancer indicates sensitivity to cisplatin by the activation of caspases.  
Low claudin expression has been linked to chemoresistance. A 
recent study showed that the malignant cells, which remain following 
conventional neoadjuvant chemotherapy in the low claudin group of 
breast cancer, are those with high CSC/TIC potential. This is likely to 
be due to CSC/TICs surviving chemotherapy48.  
CLDN11 is involved in DNA methylation mediated 
development of resistance to cisplatin49. Lowered CLDN 1 expression 
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is also associated with chemoresistance 
The mechanisms involved in claudin induced drug resistance are 
thought to involve mechanisms of drug transport, apoptosis and 
CSC/TICs.  
 
 
 
 
 
Fig 15: The Emerging role of claudins in EMT, CSC/TICs, and chemoresistance or recurrence. 
 The relationship between claudins and chemoresistance 
according to cancer type also remain to be determined, underlining the 
need for more studies in this area.  
Claudins as Biomarkers and Therapeutic Targets  
Claudin expression patterns in specific cancers are extremely 
consistent. This may translate into a role in detection and diagnosis. 
Recently CLDN 4 was detected in peripheral blood in circulating 
ovarian cancer cells.  
51  
The prognostic significance of variations of claudin expression 
is also being studied to establish clinical utility.  
Decreased expression of claudin-1 indicates poor outcome in 
many malignancies. In addition, it is a reliable predictor of tumor 
recurrence. When claudin-1 expression is low in hepatocellular 
carcinomas, the degree of dedifferentiation and portal invasion are seen 
to be more. In breast cancer claudin-1 expression is positively 
correlated with a short disease-free interval. Variations in claudin-1 
expression in different molecular subtypes of breast cancer, can mean 
that they can be used in the identification of certain subtypes. Loss of 
claudin-2 expression is  linked with increased incidence of metastasis 
in breast cancer.  
Increased CLDN4 expression is seen to markedly shorten overall 
survival and recurrence-free survival, indicating a poor prognosis50. In 
addition, studies indicate that this prognostic significance of CLDN3 or 
CLDN4 varies with the breast cancer subtype. For instance, a Japanese 
group showed that “the combination of claudin-4 and E-cadherin 
expression called CURIO accurately predicts relapse-free survival in 
breast cancer. CURIO was shown to predict prognosis, especially in 
luminal A and triple-negative subtypes of breast cancer: high 
expression of CURIO is related to worse prognosis and the converse is 
also true. The distinctive prognostic significance of claudin-3 and 
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claudin-4 in triple-negative and luminal types of breast cancer was 
analyzed in a recent report in which positive expression of claudin-3 
was associated with poor prognostic factors, whereas claudin-4 
expression was related to better prognostic factors in TNBCs.” 
Decreased CLDN7 expression has been linked to a poor 
prognosis several cancers51. In breast cancer, loss of CLDN7 
expression is associated with:  
 A higher histological grade  
 A shorter time recurrence free interval 
 Increased rate of metastasis 
Different combinations of CLDN expression can predict disease 
recurrence, as shown in a recent study by Lu et al.52, in which “the 
relationship between the expression of claudins 1, 3, 4, 7 and -8 and 
patient survival was analyzed in high-grade invasive breast cancer 
including several molecular subtypes. Low expression of all five 
claudins was mostly detected in basal-like cancers (77%), and patients 
with claudin-low tumors had significantly shorter recurrence-free 
survival, suggesting that low levels of claudin expression predict 
disease recurrence.” 
Claudins as Drug Targets in Cancer  
The four transmembrane domains and two extracellular loops 
that CLDNs possess, are potential targets for antibodies that can be 
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developed. However, they have a low immunogenicity and this is a 
roadblock in the development of appropriate antibodies. 
Recently, antibodies against the extracellular loops have been 
produced for CLDN 3 and 4.  The antibody against CLDN4 has shown 
promising antitumour activity both in vitro and in vivo. Another 
development has been the preparation of a monoclonal antibody that 
acts against both CLDN 3 and 4, which was effective in vitro and in 
vivo. This antibody induced antibody-dependent cellular cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC) in vitro and 
inhibited tumor formation in vivo53. 
Claudin-3 and claudin-4 are receptors for CPE. The exploitation 
of this property in anticancer therapy has been considered. Small 
interfering RNA (siRNA) that target CLDNs are seen to suppress 
tumour growth and metastasis54.  
With the limited studies that are available indicate the potential 
value of CLDNs as targets for drug therapy. However the transition of 
such research into clinical application will require more extensive 
research and conclusive evidence. 
TUMOUR PROTEIN 53 GENE 
The TP53 gene is situated on the short arm of chromosome 17 
and codes Tumour Protein p53. This protein is critical in assessing if 
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damaged DNA can be salvaged by repair, or if the damage is too 
extensive, in which case, further cell division will be prevented and the 
cell will undergo apoptosis. It is the most commonly mutated gene in 
human cancer 
Hereditary breast cancer can be seen as part of Li-Fraumeni 
syndrome. Somatic mutations occur in 20 – 40% of all cases of CA 
Breast.  
In any malignancy, the presence of this mutation indicates a 
poor response to treatment, and shortened survival55.  There are in fact, 
different types of mutations, each of which affects the prognosis 
differently. Specifically, those affecting the DNA-binding motifs have 
been linked with a guarded prognosis.  
Several studies have assessed the prognostic importance and 
predictive value of TP53 mutation in breast cancer. Most of them 
indicate a poor prognosis for tumours that possess this mutation, 
especially more so for those involving the DNA binding motifs56. In 
fact, theTP53 mutation has now emerged as an independent predictor 
of poor prognosis. Missense mutations as well as non-missense 
mutations of residues that bind DNA resulted in a poor prognosis, the 
latter being worse. Non missense mutations cause loss of protein 
expression, and thereby, loss of function57.  
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Although TP53 mutation independently is seen to predict poor 
prognosis, it has not been compared to a great extent with other 
markers of poor prognosis so far. For instance, in a study of women 
with node-negative breast cancer, a higher risk of recurrence and death 
was seen when there was P53 mutation along with expression of HER 
2 neu. Similar results have also been reached in expression profiling 
using micro-arrays, where it was seen that TP53 mutation was seen in 
association with profiles that indicated a poor outcome. When these 
expression profiles were excluded, the presence of a TP53 mutation 
status and size of the primary tumour were the strongest predictors of 
breast cancer survival. However, gene expression-based classification 
and tumor size gained precedence as independent predictors of survival 
when the former was included. The TP53 mutation is also strongly 
associated with the basal like molecular subtype of breast cancer58. An 
expression signature for TP53 mutation status has been identified in 
human breast cancer that is a good predictor of patient survival. 
The prognostic significance of TP53 mutations is substantial 
with the risk of death from breast cancer being in between 2 and 5. 
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Ki-67 PROLIFERATIVE INDEX 
The Ki-67 protein is exclusively seen in proliferating cells. It is 
a non-histone protein. It has a critical role in polymerase I-dependent 
ribosomal RNA synthesis. As expected, it is absent in resting cells 
(G0). In the G1 and S phases of the cell cycle, Ki-67 levels are low and 
it seen to be at its highest level during mitosis. During interphase, the 
Ki-67 antigen is seen within the cell nucleus alone. It migrates to the 
surface of the chromosomes during mitosis.  
Since it is only seen during the active phases of the cell cycle, it 
is an excellent marker for the determination of the fraction of dividing 
cells in a given cell population59.While exact cut off levels to 
categorize tumours based of fraction of proliferating cells have not 
been arrived at as yet, arbitrarily, levels above 10%–14% are taken to 
be high risk lesions in terms of prognosis.  
Its levels in a malignant tumour are determined by 
immunohistochemistry. A number of studies have verified its 
credibility as a proliferative index60. 
Rather than using the qualitative values directly to all tumours, it 
may be more prudent to consider its value in conjunction with other 
markers that have a prognostic significance, such as the IHC4 panel, 
which consists of the ER, PR and HER2 neu along with Ki67 index. 
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In the determination of residual risk in patients being treated 
prophylactically with Letrozole or Tamoxifen for the reduction of early 
breast cancer risk, Ki67 index is included in the algorithm. Further 
studies are required to accurately gauge its importance in these regards 
Predictive Role of Ki67. 
Various studies have of late shed light on the predictive role of 
expression of the response to specific chemotherapeutic agents. Several 
centres have tried to establish cutoff levels of Ki67 that can 
differentiate between Luminal A and Luminal B molecular subtypes of 
breast cancer61.  
Studies have reported that those malignancies with high Ki67 
index responded better to the addition of docetaxel to fluorouracil and 
epirubicin chemotherapy in adjuvant treatment of ER-positive tumors. 
But there is also evidence that suggests that Ki67 index has no 
predictive value when cyclophosphamide, methotrexate, and 
fluorouracil were added to endocrine therapy in hormone-responsive 
node-negative disease. Thus, the determination of areas of utility 
remains unsatisfactory. 
ER negative tumours are generally believed to be more 
responsive to adjuvant chemotherapy than their ER positive 
counterparts62. This may be explained by the fact that these tumours 
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overall are highly proliferative. Hence, the measurement of the Ki 67 
index may help predict response to neoadjuvant chemotherapy.  
Neoadjuvant Therapy and Pharmacodynamic Role of Ki67 
 In LABC, after the completion of NACT, the response of the 
tumour to such therapy is assessed and when there is a pathological 
complete response, it is a reliable predictor of disease free and overall 
survival of the patient.  
The results of the Immediate Preoperative Anastrozole, 
Tamoxifen, or Combined with Tamoxifen (IMPACT) study63and P024 
study64 of neoadjuvant letrozole vs tamoxifen demonstrated clearly that 
“the difference in the degree of Ki67 suppression between the study 
arms was the same as the difference in recurrence in equivalent large 
adjuvant trials, Arimidex, Tamoxifen Alone or Combined (ATAC) 
trial65 and Breast International Group (BIG) 1–98 trial, 
respectively.”The neoadjuvant study American College of Surgeons 
Oncology Group (ACOSOG) Z103166also produced similar results, 
with no difference in Ki67 suppression between exemestane and 
anastrozole. This concurs with the results of the MA.27 trial where 
similar rates of disease-free survival were observed in patients when 
these drugs were used in adjuvant therapy. 
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Hence, Ki 67 index is an excellent primary endpoint in 
determining the effectiveness of neoadjuvant therapy, mainly but not 
limited to endocrine therapy67. Additionally, in one therapeutic 
neoadjuvant trial that tested the activity of gefitinib when added to 
anastrozole, Ki67 was chosen to be the primary endpoint, instead of 
tumor shrinkage. When this trial showed no benefit from gefitinib by 
either the Ki67 index or by clinical response, phase III clinical trials 
were abandoned in patients with early breast cancer. 
In the P024 study, at the end of 4 months of neoadjuvant 
endocrine therapy with letrozole or tamoxifen, Ki67 index, 
pathological tumor size, node status, and ER status were seen to be 
independently associated with recurrence-free and overall survival64. A 
Preoperative Endocrine Prognostic Index (PEPI) derived from a 
combination of these factors was validated as predictive of long-term 
outcome in an independent dataset from the IMPACT trial.  
Ki67 as a Pharmacodynamic Intermediate Endpoint. 
If the Ki67 index remains unchanged early on in treatment, it 
might be due to therapeutic failure. In the IMPACT trial, the Ki 67 
index following two weeks of endocrine therapy had a stronger 
association with time to recurrence compared with pretreatment Ki67 
level. In addition, pretreatment Ki67 level was not significantly 
associated with time to recurrence in a multivariable model that 
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including the pretreatment and 2-week Ki67 values68. The pretreatment 
value is known to have prognostic importance and the change in the 
index in 2 weeks has a predictive importance. Hence, at the end of two 
weeks, it is the residual risk after endocrine therapy that is arrived at. 
The possible advantage of measuring 2-week Ki67 instead of 
pretreatment Ki67 is under evaluation in the 4000-patient 
“Perioperative Endocrine Therapy for Individualizing Care (POETIC)” 
window-of-opportunity study.  
Using tumor samples from a phase II neoadjuvant trial with 
letrozole, Ellis et al. identified a group of patients in whom the Ki67 
index was 10% or greater after 4 weeks of treatment. Thus the early 
evaluation of the Ki 67 index can be used to segregate ER-positive 
patients and subject them to NACT rather than neoadjuvant endocrine 
therapy69. Trials are now underway to further clarify this. 
Ki67 as an Eligibility Criterion for Neoadjuvant Trials. 
When a neoadjuvant trial is undertaken, it is usually to 
determine is a new therapeutic agent shows any activity against the 
malignancy being studied. Those patients with a low Ki67 index at the 
time of detection of the disease are unlikely to show any significant 
improvement. In this scenario, the pretreatment Ki67 index may be 
used to exclude such patients from trials70. 
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Neoadjuvant Chemotherapy. 
As of now, the value of Ki67 is greater with neoadjuvant 
endocrine therapy than chemotherapy. Studies have shown that the 
Ki67 index decreases in most patients undergoing neoadjuvant 
treatment and it is possible that a greater degree of reduction is 
associated with a better response71. Ki 67 index determined in residual 
tumours has a strong prognostic significance. This may help identify 
patients who would benefit from adjuvant therapy, as they would be 
the ones to benefit most from it.  
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RESULTS 
In this study, the average age of women included was 49.96 years. 
They were arbitrarily classified in to age groups of less than or equal to 
50 years and more than fifty years. 
 
Chart 1: Age  
 
There were 23 (46%) women of age more than fifty and 27 
(54%) younger than or of fifty years of age. The cancer was present in 
the right breast in 29 (58%) and in left breast in 21 (42%) of these 
women.  
 
 
 
 
Chart 2: Clinical Stage at Presentation 
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When the clinical staging was initially assessed, it was seen that 
3 (6%) women had Stage IA disease, 3 (6%) IIB, 3 (6%) IIA, 24 (48%) 
IIB, 8 (16%) IIIA, 5 (10%) IIIB and 3 (6%) metastatic Stage IV 
disease. 1 patient (2%) was a case of recurrent carcinoma. Hence Stage 
IIB disease was by far the commonest stage of presentation. The sizes 
of the primary tumours varied widely. Lesions as small as 2x2 cm and 
as large as 12x10 cm were seen. 
 
 
 
 
 
 
Chart 3: Tumour Size 
In the patient with recurrence, it presented as a 2x1 cm nodule. 
They were all single lesions clinically. Mammogram confirmed the 
absence of multicentricity and multifocality in all patients.  
 Clinical or radiological presence of suspicious lymph nodes was 
seen in 26 (52%) of patients. 
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Chart 4: Clinical/Radiological Lymphadenopathy  
Trucut biopsy taken for the confirmation of diagnosis showed 
that they were all uniformly infiltrating ductal carcinomas. Based on 
clinical stage, 33 (66%) were categorized as early breast cancer, 13 
(26%) as locally advanced breast cancer and 4 (8%) were metastatic.  
 
 
 
 
 Chart 5: Disease Categorization  
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These patients were subjected to primary surgery, neoadjuvant 
chemotherapy followed by surgery and palliative care, respectively.  
 
  
 
 
Chart 6: Treatment  
Immunohistochemistry for hormonal receptor status showed that 
30 (60%) of tumours were Estrogen Receptor positive, 25 (50%) 
Progesterone Receptor positive and 17 (34%) expressed the Human 
Epidermal Growth Factor Receptor, HER 2 neu.  
 
 
 
 
 Chart 7: Hormone Receptor Status  
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Taken together, Luminal A molecular subtype was the 
commonest, and seen in 22 (44%) of tumours, while Luminal B 
tumours constituted 8 (16%), Her 2 enriched 9 (18%) and the Basal 
Like or Triple negative tumours accounted for 11 (22%).  
Mutations of the Tumour Protein 53 and Ki 67 index were also 
assessed by Immunohistochemistry. P 53 mutations were seen in 12 
(24%) of tumours. 
 
 
 
 
Chart 8: P53 Mutation 
Ki 67 Index was quantified and the patients were divided into 
those with a high index (>15%) and a low index (<15). 
 
 
 
 
Chart 9: Ki 67 Index 
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There were 28 (56%) patients who had a low Ki67 Index and 22 
(44%) with a high Index. 
 RT-PCR was done to assess the expression of Claudins 1, 3, 4 
and 7. While CLDN 1, -3 and -4 showed low expression in 7(14%) 
patients, CLDN 4 showed low expression in 6(12%) of the patients 
who had low expression of the three other CLDNs and high expression 
in the seventh  
 
 
 
 
 
Chart 10: Expression of Claudins 1, 3, 4 & 7  
patient (Patient No. 11), as well as in one patient (Patient 19) who had 
normal levels of expression of the other three. Thus, 2 patients (4%) 
had increased expression of Claudin 4. Normal levels were seen in the 
others.   
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These results were analysed using Statistical Package for the 
Social Sciences (SPSS). It was seen that the association between the 
expression of CLDN1, -3 and -7 and the age of the patients was not 
significant, with p = 0.524. Even with the application of a continuity 
correction of 0.053, the p value remained at 0.819 
 
 
 
 
 
Chart 11: Expression of CLDN 1, 3, 4, and 7 vs. Age 
 
Similarly, the association of CLDN 4 with age had a p value of 
0.253 and hence, was also, not significant. 
CLDN Age in Years Chi-Square Test <=50 >50 Total Value df p Value 
CLDN1 Low 19 (44%) 24  (56%) 43 (100%) 
0.407 1 0.524 
Normal 4 (57%) 3 (43%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN3 Low 19 (44%) 24  (56%) 43 (100%) Normal 4 (57%) 3 (43%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN7 Low 19 (44%) 24  (56%) 43 (100%) Normal 4 (57%) 3 (43%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN4 Low 19(42%) 23(55%) 42(100%) 2.745 2 0.253 Normal 4(67%) 2(33%) 6(100%) High 0(0%) 2(100%) 2(100%)  
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Table 4: Association of Expression of CLDN 1, 3, 4 & 7 with Age                 Chart 12: Clinical Stage vs. Expression of Claudins 1, 3, 4 & 7  
   When the association of clinical stage of breast cancer with 
levels of CLDN 1, -3, -4 and -7 was analysed, it was seen that there 
was no significant association between the clinical stage of disease and 
the expression of CLDNs with p = 0.090.  
The same was true for the size of the primary tumour, and the 
association was deemed not significant at a p = 0.065. 
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CLDN 
Clinical Stage Chi-Square Test 
IA IB IIA IIB IIIA IIIB IV Recurrent Total Value df 
p Value 
CLDN1 
Normal 
3 (7%) 
3    (7%) 
3    (7%) 
22   (51) 
6 (14%) 
3    (7%) 
3   (7%) 
0   (0%) 
43    (100%) 
12.348 7 0.090 
Low 0 (0%) 
0(0%) 
0    (0%) 
2   (29%) 
2 (29%) 
2   (29%) 
0    (0%) 
1 (14%) 
7      (100%) 
High 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
CLDN3 
Normal 
3 (7%) 
3    (7%) 
3    (7%) 
22   (51) 
6 (14%) 
3    (7%) 
3   (7%) 
0   (0%) 
43    (100%) 
Low 0 (0%) 
0(0%) 
0    (0%) 
2   (29%) 
2 (29%) 
2   (29%) 
0    (0%) 
1 (14%) 
7      (100%) 
High 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
CLDN7 
Normal 
3 (7%) 
3    (7%) 
3    (7%) 
22   (51) 
6 (14%) 
3    (7%) 
3   (7%) 
0   (0%) 
43    (100%) 
Low 0 (0%) 
0(0%) 
0    (0%) 
2   (29%) 
2 (29%) 
2   (29%) 
0    (0%) 
1 (14%) 
7      (100%) 
High 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 
CLDN4 
Normal 3(7%) 3(7%) 3(7%) 
22 (52%) 
6 (14%) 
3(7%) 2(5%) 0(0%) 
42 (100%) 
22.698 14 0.065 Low 0(0%) 0(0%) 0(0%) 
2 (33%) 
2(33%) 1(17%) 0(0%) 1(17%) 100.00% 
High 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1(50%) 1(50%) 0(0%) 6 
 
Table 5: Association of Expression Claudins 1, 3, 4 & 7 with Clinical Stage
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When the association of presence of clinically and radiologically 
suspicious lymph nodes with expression of CLDN 1, -3, -7 was tested, 
it was seen to be significant with p = 0.006. (With a continuity 
correction of 5.44, p value was 0.02). The association of CLDN4 with 
clinical or radiological lymphadenopathy was significant at 0.012. The 
difference was thus, not due to chance. 
 
Chart 13: Clinical/Radiological Lymphadenopathy vs.  Expression of Claudins 1, 3, 4 & 7  
CLDNs 
Suspicious Lymph Nodes (Clinical & Radiological) Chi-Square Test 
Present Absent Total Value df p Value   Normal 19 (44%) 24 (56%) 43(100%) 
7.513 1 0.006 
CLDN1 Low 7 (100%) 0 (0%) 7(100%)   High 0 (0%) 0(0%) 0    (0%) 
CLDN3 Normal 19 (44%) 24 (56%) 43(100%) Low 7 (100%) 0 (0%) 7(100%) High 0 (0%) 0(0%) 0    (0%) 
CLDN7 Normal 19 (44%) 24 (56%) 43(100%) Low 7 (100%) 0 (0%) 7(100%) High 0 (0%) 0(0%) 0    (0%) 
CLDN4 Normal 18(43%) 24(57%) 42(100%) 8.791 2 0.012 Low 6(100%) 0(0%) 6(100%) High 2(100%) 0(0%) 2(100%) Table 6: Association of Expression Claudins 1, 3, 4 & 7 with Clinical/Radiological Lymphadenopathy 
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On analysing the association of expression of CLDNs 1, 3, and -
4 with Estrogen receptor (ER) positivity, a significant p value of 0.008 
was arrived at. (With a continuity correction of 5.046, the p value was 
0.025.) ER positivity was also found to be significantly associated with 
CLDN 4 expression (p = 0.004). 
 
 
 
 
 Chart 14: Estrogen Receptor vs. Expression of Claudins 1, 3, 4 & 7  
CLDNs ER Chi-Square Test Positive Negative Total Value df p Value 
CLDN1 Normal 29(67%) 14(33%) 43(100%) 
7.087 1 0.008 
Low 1(14%) 6(86%) 7(100%) High 0 (0%) 0(0%) 0    (0%) 
CLDN3 
Normal 29(67%) 14(33%) 43(100%) 
Low 1(14%) 6(86%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN7 
Normal 29(67%) 14(33%) 43(100%) 
Low 1(14%) 6(86%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN4 Normal 28(67%) 14(33%) 42(100%) 11.111 2 0.004 Low 0(0%) 6(100%) 6(100%) High 2(100%) 0(0%) 2(100%)  Table 7: Association of Expression of Claudins 1, 3, 4 & 7 with Estrogen Receptor 
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The association of the expression of CLDNs 1, 3, and 7 with the 
Progesterone receptor (PR) was not significant as, although the 
Pearson Chi-Square test showed a p value of 0.042, after applying a 
continuity correction of 2.658, the p value was 0.103. That of CLDN 4, 
however, was significant with p = 0.015. 
 
 
 
 
Chart 15: Progesterone Receptor vs. Expression of Claudins 1, 3, 4 & 7 
CLDNs PR Total Chi-Square Test Positive Negative Value df p value 
CLDN1 
Normal 24(56%) 19(44%) 43(100%) 
4.153 1 0.042 
Low 1(14%) 6(86%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN3 
Normal 24(56%) 19(44%) 43(100%) 
Low 1(14%) 6(86%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN7 
Normal 24(56%) 19(44%) 43(100%) 
Low 1(14%) 6(86%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN4 Normal 44(55%) 19(45%) 42(100%) 8.381 2 0.015 Low 0(0%) 6(100%) 6(100%) High 2(100%) 0(0%) 2(100%)  Table 8: Association of Expression of Claudins 1, 3, 4 & 7 with      Progesterone Receptor  
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When association of HER2 neu expression with that of CLDNS 
1, 3 and & 7 and CLDN4 was, however not significant with p=0.744 
and p =0.581, respectively. 
 
 
 
 
 
 Chart 16: HER 2 neu vs. Expression of Claudins 1, 3, 4 & 7 
 
CLDNs HER 2 neu Total Chi-Square Test Positive Negative Value df p value 
CLDN1 
Normal 15(35%) 28(65%) 43(100%) 
0.107 1 0.744 
Low 2(29%) 5(71%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN3 
Normal 15(35%) 28(65%) 43(100%) 
Low 2(29%) 5(71%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN7 
Normal 15(35%) 28(65%) 43(100%) 
Low 2(29%) 5(71%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN4 Normal 15(36%) 27(64%) 42(100%) 1.086 2 0.581 Low 1(17%) 5(83%) 6(100%) 
 High 1(50%) 1(50%) 2(100%)   Table 9: Association of Expression of Claudins 1, 3, 4 & 7 with HER 2 neu Expression  
75  
By determining ER, PR and HER 2 neu, the tumours were 
categorised into their molecular subtypes. As the area of focus of this 
study is the triple negative tumours, their association with the 
expression of CLDNs 1, 3, 4 and 7 was determined and it was found to 
be highly significant. 
 
 
 
 
 
 Chart 17: Triple Negative Tumours vs. Expression of Claudins 1, 3, 4 & 7 
  
CLDN Triple Negative Tumours Chi sqare test Yes No Total Value df p Value 
CLDN1 Normal 7 (16%) 36 (84%) 43 (100%) 
10.038 1 0.002 
Low 5 (71%) 2 (29%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN3 Normal 7 (16%) 36 (84%) 43 (100%) Low 5 (71%) 2 (29%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN7 Normal 7 (16%) 36 (84%) 43 (100%) Low 5 (71%) 2 (29%) 7 (100%) High 0(0%) 0(0%) 0(0%) 
CLDN4 Normal 7(17%) 35(83%) 42 (100%) 13.450 2 0.001 Low 5(83%) 1(17%) 6 (100%) High 0(0%) 2(100%) 2 (100%)  Table 10: Association of Expression of Claudins 1, 3, 4 & 7 with Triple Negative Tumours 
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 The loss of TP53 was analysed with respect to the expression of 
CLDN 1, 3, 4 and 7. A strong association was found with a highly 
significant p value (p = 0.000). 
 
 
 
 
 
Chart 18: Loss of P53 vs. Expression of Claudins 1, 3, 4 & 7  
CLDNs TP53 Total Chi-Square Test Lost Normal Value df p value 
CLDN1 
Normal 6(14%) 37(86%) 43(100%) 
16.996 1 0.000 
Low 6(86%) 1(14%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN3 
Normal 6(14%) 37(86%) 43(100%) 
Low 6(86%) 1(14%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN7 
Normal 6(14%) 37(86%) 43(100%) 
Low 6(86%) 1(14%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN4 
Normal 5(12%) 37(88%) 42(100%) 
21.282 2 0.000 Low 5(83%) 1(17%) 6(100%) 
High 2(100%) 0(0%) 2(100%) 
 Table 11: Association of Expression of Claudins 1, 3, 4 & 7 with Loss of TP53  
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Finally, the Ki 67 index of these patients was found to be significantly 
association with the expression of CLDN 1, 3, 4 (p = 0.001) and 
CLDN 7 (p = 0.005) 
.  
 
 
 
 Chart 19: Ki 67 Index vs. Expression of Claudins 1, 3, 4 & 7  
CLDNs Ki 67 Index Total Chi-Square Test 
Low(≤15%) High(>15%) Value df p value 
CLDN1 
Normal 28(65%) 15(35%) 43(100%) 
10.359 1 0.001 
Low 0(0%) 7(100%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN3 
Normal 28(65%) 15(35%) 43(100%) 
Low 0(0%) 7(100%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN7 
Normal 28(65%) 15(35%) 43(100%) 
Low 0(0%) 7(100%) 7(100%) 
High 0 (0%) 0(0%) 0    (0%) 
CLDN4 
Normal 27(64%) 15(36%) 42(100%) 
8.836 2 0.005 Low 0 (0%) 6(100%) 6(100%) 
High 1(50%) 1(50%) 2(100%) 
 
Table 12: Association of Expression of Claudins 1, 3, 4 & 7  with Ki 67 Index 
78  
DISCUSSION 
 Among the patients included in this study, 58% had right-sided 
breast cancer, whereas cancer of the left breast is more common in 
literature. The average age of the women included in this study was 
49.96 years, which concurs with data from several epidemiological 
studies done in India by Bhadoria et al72and  Kokiwar et al73, among 
others. It is slightly less than the median age in the Western population, 
which is 53 years74. The most common clinical stages at initial 
assessment were Stages IIB and IIIA. 48% presented in Stage IIB and 
16% in IIIA. This data also coincides with that in the above studies.  
 All tumours were single lesions and they were all uniformly 
infiltrating ductal carcinomas. This could be attributed to the limited 
number of subjects in this study. A larger number would have yielded 
variations.  
52% of patients presented suspicious lymph node enlargement. 
This data also coincides with the available demographic data for the 
Indian Subcontinent75. Metastasis to axillary nodes is generally 
regarded as the single most important variable in the prognostication of 
CA breast. Szasz et al, in a study published in 2011, describe regional 
lymph node metastasis in association with CLDN 1, 3, 4, 5 and 7. It 
was seen that CLDN 1 expression was lesser in primary tumours that 
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presented with lymph node metastasis, than in the lymph nodes 
themselves. CLDNs 3, 4 and 7 were expressed at a lower level in the 
lymph nodes, than in the primary tumour. CLDN 5 expression, 
however was seen to be higher in the metastases, than in the primary 
lesion.  
 60% of tumours showed Estrogen receptor positivity, 50 % 
Progesterone receptor positivity and 34% expressed the HER2 
Receptor. This is much higher than the levels seen in studies in the 
Indian population. Desai et al76 found ER positivity of 32.6% and PR 
positivity of 46.1% in a study conducted in 2000. More recent studies, 
such as that by Kaul et al77 in 2011 showed ER positive tumours to 
constitute 34.5 and PR positive tumours, of 36.4 in their study. The 
expression of Her 2 neu was slightly higher than the general consensus 
of 25 – 30%78,79. 
 22% of tumours were triple negative. This is higher than the rate 
found in studies in the West (11.2%) such as Dent et al74. There is a 
marked variation in the rates found in the Indian population in studies 
by Ram Prabhu et al (24.5%)80 and Suresh et al (12.5%)81. Ko et al, in 
a paper presented at the 2013 ASCO Annual Meeting, declared that the 
percentage of low claudin expression in their study the included 342 
cases of triple negative breast disease was 20.5%. 5 out of the 12 triple 
negative cases (42%) showed low expression of CLDNs 1, 3, 4 and 7.  
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TP53 mutations were found in 12 patients (24%) patients. This 
is marginally lower when compared with literature with most studies 
quoting a range of 25 – 40% in sporadic breast cancer82,83,84. In an 
interesting study published in June, 2014 by O’leary et al, the authors 
showed that expression of the mammotrophic hormone, prolactin or its 
receptor decreased the latency of tumours when there were preexisting 
p53 mutations. Most tumours thus detected were also triple negative. 
The role of prolactin in breast tumourigenesis is gaining prominence as 
several epidemiological studies have demonstrated an association. 
 The Ki 67 index was seen to be low in 28(56%) and high in 
22(44%) of tumours, where low Ki67 was taken as ≤15% and high was 
>15%. This concurs with the available literature85,86 Several studies 
indicate that while simple assessment of ER, PR and HER 2 neu status 
of tumours maybe insufficient to accurately classify breast cancer into 
its intrinsic subtypes, this stratification of Ki 67 index in to high and 
low can help differentiate Luminal A from Luminal B tumours.  
 The expression of CLDNs 1, 3, 4 and 7 determined by RT PCR 
yielded low expression of CLDN 1, 3 and 7 in 7 (14%) patients. Low 
expression of CLDN 4 was seen in 6 (12%) and increased expression 
in 2 (4%) of patients. Tokés et al reported similar results when 
studying Claudin-1, -3 and -4 proteins and mRNA expression in benign 
and malignant breast lesions in 200587. In literature, several variations 
in claudin expression that affect the tumour phenotype in different 
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ways have been described88. 
Claudin gene expression showed significant association with: 
 The presence of clinical or radiologically suspicious 
lymph nodes 
 ER status  
 PR status was only significantly associated with the 
expression of CLDN 4, and not with that of CLDN 1, 3 
and 7. 
 Triple negative tumours 
 P 53 mutation, and  
 Ki 67 index.  
Every one of these associations indicates an aggressive tumour 
phenotype. Regardless of the stage of presentation, these patients must 
be expected to have a shorter disease free survival and overall 
survival89. These tumours are often only found to have partial response 
to NACT48. 
In a study consisting of 446 cases or primary sporadic breast 
cancer, Ricardo et al88 showed that in the low claudin subtype of breast 
cancer was significantly associated while CLDN 1 was not 
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significantly associated with tumour size, the association with CLDNs 
3, 4 and 7 were significant. The presence of lymph node enlargement, 
while associated with expression of CLDNs 3 and 7, was not 
associated with the expression of CLDN 1 and 4. Histological grade 
was significantly associated with CLDNs 1, 3 and 4 but not with 
CLDN 7. ER and PR positivity was significantly associated with 
CLDN 1 and 4, but not with 3 and 7.  
In this study, significant association was not seen with age, 
clinical stage and size of primary tumour at initial assessment and HER 
2 neu expression. In addition only CLDN 4 had a significant 
association with PR status. In a study by Blanchard et al, published in 
2013, high expression of CLDN 1 was significantly associated with 
triple negative tumours in women of or above the age of 55, while 
CLDN 4 was not. In the same study, there was no association between 
the expression of CLDN 1 and tumour size. Lanigan et al in a study 
published in 2009 also found no significant association between CLDN 
4 expression and age, tumour size, histological type or 
lymphadenopathy. 
In the study by Ricardo et al quoted above, HER 2 neu 
expression only showed significant association wit CLDN1, but not 
with the rest. Ki 67 index showed no statistical significance in its 
association with any of the claudins studied. Other studies have shown 
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that the patterns of survival in patients expressing HER 2 neu varied 
with the expression of ER and PR. 
While most of the available data state the lack of an association 
between HER 2 neu and claudin expression, several studies quote that 
there is a significant association with the presence of p53 mutations. 
But this association was not analyzed in this study, and could be 
ascertained from the available data as an extension.  
In a study with 226 consecutive patients conducted between 
1996 and 2009, Lu et al showed that HER2 expression was not 
significantly associated with either increased or decreased expression 
of CLDNs 1, 3, 4, 7 and 8. This is in concurrence with our study.   
The rate of growth of the primary and progression of the disease 
may be better parameters than a single measurement of tumour size 
and the stage of the disease at initial assessment. This maybe attributed 
to the difference in threshold of these women to visit the hospital. 
Some may rush to the doctor at the slightest suggestion of a lump, 
while others, albeit rare in today’s scenario, may only come with the 
onset of pain or ulceration. 
84  
SUMMARY 
The present study was conducted to find the association between 
disease severity and hormone receptor status, P 53 mutations, KI 67 
index and expression of CLDNs 1, 3, 4 and 7. The study was 
conducted in the General Surgery Department of ESIC Medical 
College & PGIMSR over a period of 18 months. Fifty women with CA 
breast were included in the study. The mean age of women in this 
study was 49.96 years. Right-sided lesions were more common. The 
size of the primary tumour varied from 2x2 cm to 12x10 cm. The 
commonest stages of presentation were Stage IIB (48%) and Stage 
IIIA (16%). All tumours were single lesions and were 
histopathologically infiltrating ductal carcinomas. 52% had suspicious 
lymph node enlargement. 60% shower ER positivity, 50% had PR 
positivity and 24% showed expression of HER 2 neu. P 53 mutations 
were found in 24% of patients. Ki 67 index was low in 56% of patients 
and high in 44%. Low expression of CLDN1, 3 and 7 was found in 
14%, while low expression of CLDN 4 was seen in 12% of patients. 
Increased expression of CLDN 4 was found in 4%. 
There was a statistically significant association between the 
expression of CLDNs 1, 3, 4 and 7 and: 
 The presence of clinically or radiologically suspicious 
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lymph nodes 
 ER status 
 PR status was associated with CLDN 4 expression alone 
 Triple negative tumours 
 P 53 mutation, and  
 Ki 67 index.  
There was no association, however, with the age of the patient, 
clinical stage at presentation, tumour size, HER 2 neu expression and 
that of CLDN 1, 3 and 7 with PR status. 
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CONCLUSION 
The present study concludes that there is a significant 
association between the alterations in expression of CLDNs 1, 3, 4 and 
7 and: 
 The presence of clinical or radiological lymphadenopathy 
 ER status 
 PR status was associated only with CLDN 4 expression 
 Triple negative tumours 
 Loss of TP53, and 
 Ki67 Index 
There was no significant association between the expression of 
these CLDNs and the age of the patient, clinical stage of presentation, 
HER2 neu expression and that of CLDN 1, 3 and 7 with PR status. 
While this is purely an observational study, it has helped 
establish a baseline demographic profile of patients with breast cancer 
in the present set up. This information can be carried forward and used 
to formulate larger studies that can verify the above findings and their 
statistical authenticity.  It can also help design studies where 
parameters such as response to chemotherapy by pathological cure 
rate, recurrence free survival and overall survival can be ascertained.  
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ANNEXURE I 
       S. No. 
PROFORMA 
Name: 
Age/Sex: 
Side and Size of Tumour: 
Clinical Stage: 
Multifocality/Multicentricity by Mammogram:  
Lymph Nodes (Clinical/Radiological) (Yes/No): 
 Trucut Biopsy: 
o Diagnosis: 
o IHC: 
o ER: 
o PR: 
o HER 2 neu: 
o P 53:  
o Ki67 Index: 
RT-PCR for Expression of: 
 CLDN1: 
 CLDN3: 
 CLDN4: 
 CLDN7: 
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ANNEXURE II 
                                                     INFORMED CONSENT  Informed consent for patients who are operated on in ESI-PGIMSR hospital, 
and whom we are inviting to participate in the research titled   “Correlation 
of Disease Severity, Estrogen, Progesterone & Epidermal Growth 
Factor Receptor Status with Altered Expression of Claudins 1, 3, 4 & 7, 
TP53 & Ki67 antibody in Carcinoma Breast” AT ESIC Medical College 
& PGIMSR, KK Nagar, Chennai, 2013-14. Dr. Veena Bheeman, M.S. 
(General surgery) post graduate is the principal investigator of this research 
under ESIC Medical College & PGIMSR, Chennai. 
 
Part I: INFORMATION SHEET 
 
Introduction  
We, Dr. Veena Bheeman, 1st Year General Surgery PG, guided by 
Dr.R.Anbazhakan, Professor & HOD of Surgery, are going to give you 
information and invite you to be a part of this research. Before you decide, you 
can talk to anyone of us you feel comfortable with about the research. This 
consent form may contain words that you do not understand. Please ask us to 
stop as we go through the information and we will take time to explain. If you 
have questions later, you can ask us. 
Purpose of the research 
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We will be studying whether there is correlation between the disease severity, 
estrogen, progesterone & epidermal growth factor receptor status with altered 
expression of Claudins 1, 3, 4 & 7, TP53 & Ki67 antibody in carcinoma breast.  
Type of Research 
This research will involve your participation in a non-experimental manner, with 
assured privacy and confidentiality. 
Right to Refuse or Withdraw   
 
Your participation is strictly voluntary. Refusal to participate will not affect 
subsequent services to you 
 
Procedures  
If you give consent to participate in this study, we will ask you questions 
regarding your disease. A history will be taken recording symptoms, duration of 
disease and a family history of similar illness. As per the research protocol, we 
will perform the diagnostic, staging, preanaethetic and general investigations 
required to assess your health in general and your illness in particular. After 
assessment of your illness, the available treatment options will be discussed with 
you. If surgery is feasible and you decide to undergo the same, the tissue that is 
operated on and removed inclusive of the tumour and glands of the armpit will 
be sent for histopathological examination as is routinely done with all operated 
specimens. Pathological grading of your the will be performed along with gene 
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expression studies for Claudins 1, 3, 4 and 7, p53 and ki67 antibody and 
immunohistochemistry for estrogen, progesterone & EGFR status. 
The severity of your disease as assessed in the preoperative, intraoperative and 
postoperative periods will be correlated with the expression of Claudins 1, 3, 4 
& 7, TP53 and Ki67 antibody and positivity or negativity of estrogen, 
progesterone and EGFR status. 
Confidentiality  
All information you provide will be kept confidential. Your name will not be 
used in any way. 
Whom to Contact 
If you have any questions, you can ask them now or later. If you wish to ask 
questions later, you may contact: 
Dr. Veena Bheeman , General Surgery PG  
Ph no: 9952372160   
Guide: Dr R,Anbazhakan, Professor & HOD Of Surgery & Dr. Uday Shamrao 
Kumbhar, Associate Professor Of Surgery, Department of General Surgery, 
ESIC Medical College & PGMSR , KK NAGAR, Chennai-78   
This proposal has been reviewed and approved by Institute Ethics 
Committee, which is a committee whose task is to make sure that research 
participants are protected from any harm.   
               If you have any questions regarding any part of the study, please feel 
free to ask. 
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Part II: CERTIFICATE OF CONSENT 
I have read the information in the consent form (or it has been read to me.) I 
was free to ask any questions and they have been answered. I understand 
what is being requested of me as a participant in this study.  I have been 
given satisfactory answers to my questions.  I certify that I am more than 18 
years of age. I freely consent to participate in the study called   “Correlation 
of Disease Severity, Estrogen, Progesterone & Epidermal Growth 
Factor Receptor Status with Altered Expression of Claudins 1, 3, 4 & 7, 
TP53 & Ki67 antibody in Carcinoma Breast” at ESIC Medical College & 
PGIMSR,KK Nagar,Chennai, 2012-13.   
I have read and understood this consent form and the information provided 
to me. 
I have been explained about the nature of the study. 
My rights and responsibilities have been explained by the investigator 
I agree to cooperate with the investigator. 
Currently I am not participating in any research study. 
I hereby give permission to the investigators to release the information 
obtained from me as a result of participation in the study to the regulatory 
authorities, government agency, ethics committee. I understand that they 
may inspect my original records. 
My records will be kept confidential  
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I have decided to participate in the study. 
As I was not able to read, the consent form has been read out to me by the 
investigator and all my questions have been answered and I give my consent 
with my free will. 
 
______________________________________     
Name of Participant  
 
________________________                           ______________ 
Sign of Participant                                         Signature of Investigator  
Date 
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ANNEXURE III 
Informed Consent in Tamil 
 
